UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
SAN FRANCISCO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) , a biotechnology company developing therapeutics to slow,...
Clinical Trial
Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA- -Initial Label Would Include...
electroCore Engages FNK IR to Execute Expanded Investor Relations Program
ROCKAWAY, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced...
Milestone Pharmaceuticals to Host Investor KOL Event
Learnings from the Field: Managing PSVT and Studying AFib-RVR in the Community Setting Hosted 10 am ET, Tuesday, October 8,...
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
DURHAM, N.C., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing...
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024NEW YORK and VIENNA, Sept. 24,...
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for...
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified...
Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress
London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of...
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, Mass., Sept. 24,...
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disordersNEW YORK,...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept....
Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma
Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies Partnership builds on long-term...
Oxford-Harrington Rare Disease Centre to Host Symposium on Pioneering Research and Innovation in Rare Disease Treatments
OXFORD, UK and CLEVELAND, Ohio, US, 24th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the...
AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral...
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — —...
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy
Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of...
BIOPHYLE LAUNCHING COMMERCIALIZATION TRAINING PROGRAM FOR ARKANSAS LIFE SCIENCE RESEARCHERS
BENTONVILLE, Ark., Sept. 23, 2024 /PRNewswire/ -- biophyle—a not-for-profit educational institution fostering collaboration between scientists and clinicians in Arkansas and...